- |||||||||| metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal, IO biomarker: Adropin ameliorates reproductive dysfunctions in letrozole-induced PCOS mouse. (Pubmed Central) - Mar 14, 2025 Notably, adropin shows more efficacy than metformin in treating reproductive abnormalities in PCOS mice, as evidenced by early regularization of cyclicity and enhanced ovarian expression of 3?-HSD and aromatase proteins. Thus, adropin may be an alternative therapeutic option for managing PCOS.
- |||||||||| letrozole / Generic mfg.
Journal: Letrozole-induced reversible acute heart failure. (Pubmed Central) - Mar 12, 2025 It may rarely cause cardiac side effects. It is very important to make patients aware of these issues and to be consulted by cardiology in case of possible cardiac symptoms.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS. (Pubmed Central) - Mar 12, 2025 Altogether, the present results demonstrate that probiotics significantly ameliorated hypothalamic amenorrhea by mitigating hypothalamic lipid accumulation, suppressed inflammation, and replenished antioxidants. Crucially, probiotics enhanced hypothalamic kisspeptin levels, a key regulator of reproductive function, highlighting their potential as a therapeutic strategy for restoring ovarian function in PCOS.
- |||||||||| diacerein / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Pain sensation and emotion induced by aromatase inhibitors: a new mouse model. (Pubmed Central) - Mar 10, 2025 Administration of diacerein partially alleviated pain-related behaviors. This model provides a valuable platform for exploring the cellular and molecular mechanisms of AI treatment and evaluating potential therapeutic interventions.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Journal: OATP1B-type transport function is a determinant of aromatase inhibitor-associated arthralgia susceptibility. (Pubmed Central) - Mar 10, 2025 In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity.
- |||||||||| letrozole / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: MITO32: Efficacy of Letrozole in Recurrent Ovarian Cancer (clinicaltrials.gov) - Mar 7, 2025 P3, N=86, Terminated, Capecitabine combined with letrozole have showed a trend towards improvement in progression free survival with potential more benefit to certain sub-groups and the combination showed acceptable safety profile consistent with the established known safety profile of both letrozole and capecitabine. N=236 --> 86 | Trial completion date: Dec 2022 --> Nov 2024 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Nov 2024; Logistical problems impacting the speed of enrolment
- |||||||||| metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Ovulation induction in anovulatory PCOS women. (Pubmed Central) - Mar 6, 2025 Combining these treatments with dietary and lifestyle interventions, such as an anti-inflammatory diet, nutritional education, and personalized exercise programs, can enhance treatment outcomes. Through an integrated approach, significant improvements in metabolic health and reproductive function for women with PCOS are possible.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Lepidium Sativum (Pubmed Central) - Mar 6, 2025 LSSE exhibits potent protective effects against PCOS, surpassing metformin in several aspects. LSSE acts through multi-mechanistic action, including anti-inflammatory, antioxidant, metabolic, and hormone-balancing properties, along with its positive impact on fertility, suggesting that LSSE could be a promising natural alternative for PCOS management.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Androgens enhance recognition memory and dendritic spine density in the hippocampus and prefrontal cortex of ovariectomized female rats. (Pubmed Central) - Mar 1, 2025 Lastly, we used the aromatase inhibitor, letrozole, to discriminate between potential androgenic and estrogenic effects of androgens on behavior...The present results expand previous information on gonadal hormone actions and show that, in addition to estrogens, androgens also improve memory and increase spine density in brains of OVX female rats. While requiring further investigation, these observations provide a basis for therapeutic interventions in the treatment of menopausal, age or disease related memory loss.
- |||||||||| letrozole / Generic mfg.
Journal: Exploring new frontiers in oncofertility preservation: a case of ovarian stimulation during pregnancy. (Pubmed Central) - Feb 27, 2025 While requiring further investigation, these observations provide a basis for therapeutic interventions in the treatment of menopausal, age or disease related memory loss. This case highlights the feasibility of adapting random-start ovarian stimulation protocols during pregnancy, warranting further investigation in similar clinical scenarios.
- |||||||||| letrozole / Generic mfg.
Journal: Fertility stimulation protocols in women with cancer. (Pubmed Central) - Feb 26, 2025 For women with a diagnosis of breast cancer, and with the agreement of the treating oncologist, the stimulation protocol should include an aromatase inhibitor such as letrozole to reduce the circulating estradiol levels. All patients should have a gonadotropin-releasing hormone trigger to eliminate the risk of ovarian hyperstimulation syndrome and facilitate timely return for cancer therapy.
- |||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Alopecia as a side effect of fertility treatments in women () - Feb 26, 2025 - Abstract #AAD2025AAD_3544; Given the psychosocial consequences associated with both infertility and alopecia independently, patients experiencing both may simultaneously carry an unrecognized mental health burden. A better understanding of the prevalence, consequences, and factors influencing ART-associated alopecia is needed to better enhance patient experiences and optimize patient care.
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Effect of ALA Combined with Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (clinicaltrials.gov) - Feb 24, 2025 P3, N=150, Recruiting, A better understanding of the prevalence, consequences, and factors influencing ART-associated alopecia is needed to better enhance patient experiences and optimize patient care. Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
- |||||||||| letrozole / Generic mfg.
Journal: Adropin-Driven Browning: Targeting M2 Macrophages to Combat PCOS. (Pubmed Central) - Feb 20, 2025 We believe that the combination of trastuzumab, hormone suppression, and abemaciclib is a practicable and effective treatment for HER2-positive and HR-positive metastatic BC in premenopausal patients who cannot tolerate the first-line chemotherapy. In the present study, the serum levels of adropin were significantly lower (P
- |||||||||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis, fulvestrant / Generic mfg.
Journal, Real-world evidence: Initial real-world experience with ribociclib in advanced breast cancer. (Pubmed Central) - Feb 18, 2025 Although objective response rates were modest in this mixed cohort of heavily pretreated patients, ribociclib combined with letrozole or fulvestrant has shown robust PFS and OS in real-world practice. AEs related treatment discontinuation rate is higher than that reported in clinical trials with stringent inclusion criteria.
- |||||||||| Journal: Molecular mechanism underlying cardioprotective effect of dehydroepiandrosterone on endoplasmic reticulum stress induced apoptosis in human vascular smooth muscle cells and human umbilical vein endothelial cells. (Pubmed Central) - Feb 12, 2025
DHEA was utilized to inhibit the apoptotic effects of DTT, while estrogen receptor (ER) antagonists ICI 182,780 and G15, the androgen receptor (AR) antagonist flutamide and the aromatase inhibitor letrozole were used to identify the receptors activated during DHEA treatment in HVSMCs and HUVECs...Furthermore, the primary receptor signaling pathways were identified using signaling pathway blockers: LY294002 (PI3K blocker), SP600125 (JNK blocker), and U0126 (ERK1/2 blocker)...Our study has identified a novel mechanism underlying the cardioprotective effects of DHEA. Specifically, DHEA may mitigate ERS-induced cell apoptosis by activating estrogen receptors ER?, ER?, and GPER via the activated JNK pathway.
- |||||||||| letrozole / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle (clinicaltrials.gov) - Feb 12, 2025 P=N/A, N=200, Completed, Specifically, DHEA may mitigate ERS-induced cell apoptosis by activating estrogen receptors ER?, ER?, and GPER via the activated JNK pathway. Recruiting --> Completed | Trial completion date: Dec 2022 --> Feb 2025 | Trial primary completion date: Nov 2022 --> Feb 2025
- |||||||||| letrozole / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: LEILA-1: Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (clinicaltrials.gov) - Feb 12, 2025 P1, N=90, Active, not recruiting, Recruiting --> Completed | Trial completion date: Dec 2022 --> Feb 2025 | Trial primary completion date: Nov 2022 --> Feb 2025 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> Jun 2025
- |||||||||| letrozole / Generic mfg.
Journal: Acetate abates adipose-ovarian endocrinometabolic disturbance in experimentally induced polycystic ovarian syndrome. (Pubmed Central) - Feb 10, 2025 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> Jun 2025 Overall, the present results suggest that acetate ameliorates adipose-ovarian metabolic and endocrine disruptions that accompany PCOS, and these beneficial effects of acetate are associated with reduction of HDAC2 levels and elevation of mitofusin 2/sirtuin-1.
|